119 related articles for article (PubMed ID: 38693630)
1. Negative 18F-Piflufolastat PET/CT, But Positive 18F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer.
Ulaner GA
Clin Nucl Med; 2024 May; ():. PubMed ID: 38693630
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan.
Xu G; Lu Y
Clin Nucl Med; 2022 Apr; 47(4):378-379. PubMed ID: 35020642
[TBL] [Abstract][Full Text] [Related]
4. A bicentric retrospective analysis of clinical utility of
Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
[TBL] [Abstract][Full Text] [Related]
5. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
7. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
8. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18 F PET/CT in prostate cancer patients in early biochemical failure.
Maliha PG; Nolet B; Ebrahim A; Abikhzer G; Chaussé G; Bahoric B; Niazi T; Probst S
Nucl Med Commun; 2023 Mar; 44(3):187-193. PubMed ID: 36525002
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
[TBL] [Abstract][Full Text] [Related]
10.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
11. Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma.
Gu J; Lu Y; Xu G
Clin Nucl Med; 2022 Mar; 47(3):255-257. PubMed ID: 34392287
[TBL] [Abstract][Full Text] [Related]
12. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
13. The Diagnostic Role of
Wang R; Shen G; Huang M; Tian R
Front Oncol; 2021; 11():684629. PubMed ID: 34222008
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
15. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy.
Payne H; Bomanji J; Bottomley D; Scarsbrook AF; Teoh EJ;
Nucl Med Commun; 2022 Feb; 43(2):201-211. PubMed ID: 34669678
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.
Garza D; Kandathil A; Xi Y; Subramaniam RM
Nucl Med Commun; 2021 Aug; 42(8):907-913. PubMed ID: 33741863
[TBL] [Abstract][Full Text] [Related]
19. [
Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
[TBL] [Abstract][Full Text] [Related]
20. Positivity Rate of [
Bulbul JE; Grybowski D; Lovrec P; Solanki AA; Gabriel MS; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2022 Feb; 24(1):42-49. PubMed ID: 34480289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
